Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma

被引：0
|
作者：
Garfall, Alfred L.
Nooka, Ajay K.
van de Donk, Niels W. C. J.
Moreau, Philippe
Bhutani, Manisha
Oriol, Albert
Martin, Thomas G.
Rosinol, Laura
Mateos, Maria-Victoria
Bahlis, Nizar J.
Popat, Rakesh
Besemer, Britta
Martinez-Lopez, Joaquin
Krishnan, Amrita Y.
Delforge, Michel
Huang, Lin
Vishwamitra, Deeksha
Stephenson, Tara
Chastain, Katherine
Sidana, Surbhi
机构：
[1] Penn Med Abramson Canc Ctr, Philadelphia, PA USA
[2] Emory Univ, Winship Canc Inst, Atlanta, GA USA
[3] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Amsterdam, Netherlands
[4] Univ Hosp Hotel Dieu, Hematol Clin, Nantes, France
[5] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
[6] Hosp Badalona Germans Trias & Pujol, Inst Catal Oncol, Badalona, Spain
[7] Hosp Badalona Germans Trias & Pujol, Inst Josep Carreras, Badalona, Spain
[8] Univ Calif San Francisco, San Francisco, CA USA
[9] IDIBAPS, Hosp Clin Barcelona, Barcelona, Spain
[10] Hosp Univ Salamanca, Inst Invest Biomed Salamanca IBSAL, Centro Invest Canc IBMCC USAL, CSIC, Salamanca, Spain
[11] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada
[12] Univ Coll London Hosp, NHS Fdn Trust, London, England
[13] Univ Hosp Tubingen, Tubingen, Germany
[14] Hosp 12 Octubre, Hematol, Madrid, Spain
[15] City Hope Comprehens Canc Ctr, Duarte, CA USA
[16] Univ Leuven, Leuven, Belgium
[17] Johnson & Johnson Innovat Med, Spring House, PA USA
[18] Johnson & Johnson Innovat Med, Raritan, NJ USA
[19] Stanford Univ, Sch Med, Stanford, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7540
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma
    Popat, Rakesh
    Nooka, Ajay
    van de donk, Niels
    Moreau, Philippe
    Bhutani, Manisha
    Oriol, Albert
    Martin, Thomas
    Rosinol, Laura
    Mateos Manteca, Maria-Victoria
    Bahlis, Nizar J.
    Garfall, Alfred
    Besemer, Britta
    Martinez-Lopez, Joaquin
    Krishnan, Amrita
    Delforge, Michel
    Huang, Lin
    Vishwamitra, Deeksha
    Stephenson, Tara
    Chastain, Katherine
    Sidana, Surbhi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S80 - S80
  • [2] Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
    Garfall, Alfred L.
    Nooka, Ajay K.
    van de Donk, Niels W. C. J.
    Moreau, Philippe
    Bhutani, Manisha
    Oriol, Albert
    Martin, Thomas G.
    Rosinol, Laura
    Mateos, Maria-Victoria
    Bahlis, Nizar
    Popat, Rakesh
    Besemer, Britta
    Martinez-Lopez, Joaquin
    Krishnan, Amrita Y.
    Delforge, Michel
    Huang, Lin
    Vishwamitra, Deeksha
    Stephenson, Tara
    Chastain, Katherine
    Sidana, Surbhi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S548 - S548
  • [3] Longer-Term Follow-Up of Patients Receiving Prophylactic Tocilizumab for Cytokine Release Syndrome in the Phase 1/2 MajesTEC-1 Study of Teclistamab in Relapsed/Refractory Multiple Myeloma
    Rosinol, Laura
    Garfall, Alfred
    Benboubker, Lotfi
    Uttervall, Katarina
    Groen, Kaz
    van de Donk, Niels
    Matous, Jeffrey
    Vishwamitra, Deeksha
    Hodin, Caroline
    Stephenson, Tara
    Qi, Keqin
    Zuppa, Athena
    Chastain, Katherine
    Mateos Manteca, Maria-Victoria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S84 - S85
  • [4] Higher Teclistamab Step-up Dosing in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Results from the Majestec-1 Trial
    Matous, Jeffrey, V
    van de Donk, Niels W. C. J.
    Oriol, Albert
    Garfall, Alfred L.
    Rodriguez-Otero, Paula
    Chalopin, Thomas
    Dachs, Laura Rosinol
    Uttervall, Katarina
    Mateos, Maria- Victoria
    Trancucci, Danielle
    Carde, Natalia Quijano
    Hodin, Caroline
    Stephenson, Tara
    Zuppa, Athena
    Chastain, Katherine
    Karlin, Lionel
    BLOOD, 2024, 144 : 4749 - 4750
  • [5] Impact of COVID-19 on Outcomes With Teclistamab in the Phase 1/2 MajesTEC-1 Study in Patients With Relapsed/Refractory Multiple Myeloma
    Usmani, Saad
    Bahlis, Nizar J.
    Costa, Luciano
    Mateos Manteca, Maria-Victoria
    Nooka, Ajay
    Perrot, Aurore
    Thaman, Pragya
    Qi, Keqin
    Uhlar, Clarissa
    Chastain, Katherine
    Doyle, Margaret
    van de Donk, Niels
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S93 - S93
  • [6] Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1
    Xin Miao
    Liviawati S. Wu
    Shun Xin Wang Lin
    Yan Xu
    Yang Chen
    Yuki Iwaki
    Rachel Kobos
    Tara Stephenson
    Kristy Kemmerer
    Clarissa M. Uhlar
    Arnob Banerjee
    Jenna D. Goldberg
    Danielle Trancucci
    Amit Apte
    Raluca Verona
    Lixia Pei
    Rachit Desai
    Kathleen Hickey
    Yaming Su
    Daniele Ouellet
    Mahesh N. Samtani
    Yue Guo
    Alfred L. Garfall
    Amrita Krishnan
    Saad Z. Usmani
    Honghui Zhou
    Suzette Girgis
    Targeted Oncology, 2023, 18 : 667 - 684
  • [7] Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study
    van de Donk, Niels W. C. J.
    Bahlis, Nizar
    Costa, Luciano J.
    Mateos, Maria-Victoria
    Nooka, Ajay K.
    Perrot, Aurore
    Garfall, Alfred L.
    Thaman, Pragya
    Qi, Keqin
    Uhlar, Clarissa
    Chastain, Katherine
    Doyle, Margaret
    Usmani, Saad Z.
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [8] Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
    van de Donk, Niels
    Moreau, Philippe
    Garfall, Alfred
    Bhutani, Manisha
    Oriol, Albert
    Nooka, Ajay
    Martin, Thomas
    Rosinol, Laura
    Mateos, Maria-Victoria
    Bahlis, Nizar
    Popat, Rakesh
    Besemer, Britta
    Martinez Lopez, Joaquin
    Krishnan, Amrita
    Delforge, Michel
    Trancucci, Danielle
    Verona, Raluca
    Stephenson, Tara
    Chastain, Katherine
    Sidana, Surbhi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S477 - S478
  • [9] Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1
    Miao, Xin
    Wu, Liviawati S.
    Lin, Shun Xin Wang
    Xu, Yan
    Chen, Yang
    Iwaki, Yuki
    Kobos, Rachel
    Stephenson, Tara
    Kemmerer, Kristy
    Uhlar, Clarissa M.
    Banerjee, Arnob
    Goldberg, Jenna D.
    Trancucci, Danielle
    Apte, Amit
    Verona, Raluca
    Pei, Lixia
    Desai, Rachit
    Hickey, Kathleen
    Su, Yaming
    Ouellet, Daniele
    Samtani, Mahesh N.
    Guo, Yue
    Garfall, Alfred L.
    Krishnan, Amrita
    Usmani, Saad Z.
    Zhou, Honghui
    Girgis, Suzette
    TARGETED ONCOLOGY, 2023, 18 (05) : 667 - 684
  • [10] Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
    van de Donk, Niels W. C. J.
    Moreau, Philippe
    Garfall, Alfred L.
    Bhutani, Manisha
    Oriol, Albert
    Nooka, Ajay K.
    Martin, Thomas G.
    Rosinol, Laura
    Mateos, Maria-Victoria
    Bahlis, Nizar J.
    Popat, Rakesh
    Besemer, Britta
    Martinez-Lopez, Joaquin
    Krishnan, Amrita Y.
    Delforge, Michel
    Trancucci, Danielle
    Verona, Raluca
    Stephenson, Tara
    Chastain, Katherine
    Sidana, Surbhi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345